TABLE 1.
Patient Demographics and Tumor Characteristics
| Characteristic | Arm A (ramucirumab + osimertinib) | Arm B (osimertinib) | Total |
|---|---|---|---|
| Age, years, median (range) | 65 (37-83) | 65 (41-83) | 65 (37-83) |
| Sex, No. (%) | |||
| Male | 27 (29.0) | 13 (28.3) | 40 (28.8) |
| Female | 66 (71.0) | 33 (71.7) | 99 (71.2) |
| Race, No. (%) | |||
| White | 60 (64.5) | 26 (56.5) | 86 (61.9) |
| Asian | 24 (25.8) | 10 (21.7) | 34 (24.5) |
| Black | 3 (3.2) | 2 (4.4) | 5 (3.6) |
| Other | 6 (6.5) | 8 (17.4) | 14 (10.1) |
| EGFR mutations, No. (%) | |||
| Del 19 | 64 (68.8) | 32 (69.6) | 96 (69.1) |
| L858R | 29 (31.2) | 14 (30.4) | 43 (30.9) |
| CNS metastasis, No. (%) | |||
| No | 53 (57.0) | 22 (47.8) | 75 (54.0) |
| Yes | 40 (43.0) | 24 (52.2) | 64 (46.0) |
| Previous chemotherapy, No. (%) | |||
| No | 84 (90.3) | 42 (91.3) | 126 (90.7) |
| Yes | 9 (9.7) | 4 (8.7) | 13 (9.4) |
| ECOG PS, No. (%) | |||
| PS 0 | 31 (33.3) | 18 (39.1) | 49 (35.3) |
| PS 1 | 62 (66.7) | 28 (60.9) | 90 (64.8) |
| Smoking history, No. (%) | |||
| Never | 64 (68.8) | 29 (63.0) | 93 (66.9) |
| Current | 1 (1.1) | 1 (2.2) | 2 (1.4) |
| Former | 28 (30.1) | 15 (32.6) | 43 (30.9) |
| Not collected | 0 | 1 (2.2) | 1 (0.7) |
| Tumor histology, No. (%) | |||
| Adenocarcinoma | 83 (89.3) | 41 (89.1) | 124 (89.2) |
| Adenosquamous | 1 (1.1) | 1 (2.2) | 2 (1.4) |
| Not otherwise specified | 9 (9.7) | 4 (8.7) | 13 (9.4) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; PS, performance status.